Altimmune, Inc. (NASDAQ: ALT) reported Q2 EPS of ($0.35), in-line with the analyst estimate of ($0.35). Revenue for the quarter came in at $5 thousand versus the consensus estimate of $714 million.

For earnings history and earnings-related data on Altimmune, Inc. (ALT) click here.